Sequence: GRKKRRQRRRCG-NH2
| Experiment Id | EXP002348 |
|---|---|
| Paper | Suppression of tumor growth by systemic delivery of anti-VEGF siRNA with cell-penetrating peptide-mo |
| Peptide | Tat-CG analog |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | N/P 10–30 |
| Rna Concentration | 1 µg |
| Mixing Ratio | N/P = 10–30 |
| Formulation Format | polymeric micelle |
| Formulation Components | MPEG–PCL-SS-Tat-CG + siVEGF |
| Size Nm | 100.00 |
| Zeta Mv | 7.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | S-180 sarcoma cells |
| Animal Model | |
| Administration Route | cell culture |
| Output Type | gene knockdown |
| Output Value | VEGF secretion significantly reduced (ELISA) |
| Output Units | |
| Output Notes | Higher silencing at higher N/P ratios; comparable or superior to LipoTrust |
| Toxicity Notes | No significant cytotoxicity (WST-8) |
| Curation Notes |